Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates November 16, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit November 12, 2020 • 4:31 PM EST
Tonix Pharmaceuticals to Participate in Upcoming November Conferences November 11, 2020 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit November 9, 2020 • 4:15 PM EST
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights November 9, 2020 • 8:30 AM EST
Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics October 15, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis September 29, 2020 • 4:05 PM EDT
Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs September 28, 2020 • 4:15 PM EDT
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19? September 17, 2020 • 9:17 AM EDT